Resource Center

Your Opinion Counts

Supported by independent educational grants from Daiichi Sankyo, Inc., & Eli Lilly and Company, Medtronic, Inc., and The Medicines Company.

What's New
Abstract
Abstracts
Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease.
Wang TY, Angiolillo DJ, Cushman M, et al. J Am Coll Cardiol. 2012;59:891-900.
Abstract
Abstracts
Causes of delay and associated mortality in patients transferred with ST-segment-elevation myocardial infarction.
Miedema MD, Newell MC, Duval S, et al. Circulation. 2011;124:1636-1644
Abstract
Abstracts
International variation in and factors associated with hospital readmission after myocardial infarction.
Kociol RD, Lopes RD, Clare R, et al. JAMA. 2012;307:66-74.
Abstract
Abstracts
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Parodi G, Marcucci R, Valenti R, et al. JAMA. 2011;306:1215-1223.
Abstract
Abstracts
Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation.
Cheema AN, Mohammad A, Hong T, et al. J Am Coll Cardiol. 2011;58:1445-1454.
Abstract
Abstracts
Anti-platelet therapy: glycoprotein IIb-IIIa antagonists.
Schneider DJ. Br J Clin Pharmacol. 2011;72:672-682.
Abstract
Abstracts
Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study.
Patti G, Bárczi G, Orlic D, et al. J Am Coll Cardiol. 2011;58:1592-1599.
Abstract
Abstracts
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function.
Melloni C, James SK, White JA, et al. Am Heart J. 2011;162:884-892.e1.
Abstract
Abstracts
Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome.
Friedland S, Eisenberg MJ, Shimony A. Am J Cardiol. 2011;108:1244-1251. Review.
Abstract
Abstracts
Triple antiplatelet therapy in acute coronary syndromes.
Valgimigli M, Minarelli M. Drugs. 2011;71:1703-1719.